Indegene credit ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024

0.0	0.0	0.0	403
−1,481	−1,481	−1,664	−584
0.00×	0.00×	0.00×	0.28×
−0.47×	−0.47×	−0.64×	−0.41×
0.00×	0.00×	0.00×	0.80×
−2.17×	−2.39×	−3.11×	−1.16×
25.52×	25.52×	20.64×	8.69×
0.0%	0.0%	0.0%	22.0%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INDGN₹593.45

Indegene Ltd.

· Pharma & Health

₹ CrorePeersSYNGENE LTTS GRANULES JUBLPHARMA KIMS ERIS EMCURE ONESOURCEMcap ₹14,272 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Total Debt	403.1	0.0	0.0	0.0
Net Debt	-584.4	-1,664.3	-1,481.4	-1,481.4
Total Debt/Equity	0.28	0.00	0.00	0.00
Net Debt/Equity	-0.41	-0.64	-0.47	-0.47
Total Debt/EBITDA	0.80	0.00	0.00	0.00
Net Debt/EBITDA	-1.16	-3.11	-2.39	-2.17
Interest Coverage (EBIT/Interest)	8.69	20.64	25.52	25.52
Total Debt/Total Capital %	22.00	0.00	0.00	0.00

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.